Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

NCT03300843 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

NIH

Sponsor class

Stopped slow accrual

Conditions

Melanoma
Gastrointestinal Cancer
Breast Cancer
Ovarian Cancer
Pancreatic Cancer

Interventions

BIOLOGICAL: Peptide loaded dendritic cell vaccine

Sponsor

National Cancer Institute (NCI)